The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Borowczyk, Martyna; Wojtaszewska, Marzena; Lewandowski, Krzysztof; Gil, Lidia; Lewandowska, Maria; Lehmann-Kopydłowska, Agata; Kroll-Balcerzak, Renata; Balcerzak, Andrzej; Iwoła, Małgorzata; Michalak, Michał; Komarnicki, Mieczysław
• Is Part Of: Thrombosis research. Volume 135:Issue 2(2015)
• Page Start: 272
• Page End: 280
• Publication Date: 2015-02
• Subjects: Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2014.11.006
• Languages: English
• ISSNs: 0049-3848

Abstract

<abstract abstract-type="author" id="ab0005"> <title id="st0005">Abstract</title> <sec> <title id="st0010">Introduction</title> <p id="sp0005">Patients with Philadelphia-negative myeloproliferative neoplasms (Ph<sup>-</sup> MPNs) are at increased risk of thromboembolic and hemorrhagic complications. The aim of the study was to determine the relationship between <italic>JAK2</italic> V617F mutational status, <italic>JAK2</italic> V617F allele burden and the risk of vascular complications occurrence.</p> </sec> <sec> <title id="st0015">Materials and methods</title> <p id="sp0010">Analysis was performed in a cohort of 186 patients diagnosed with polycythemia vera (53), essential thrombocythemia (114), primary myelofibrosis (11), and unclassified MPN (8). The risk of vascular complications development was analyzed in 126 <italic>JAK2</italic> V617F-positive patients with respect to allele burden assessed with allele-specific 'real-time' quantitative polymerase chain reaction (AS RQ-PCR).</p> </sec> <sec> <title id="st0020">Results</title> <p id="sp0015">Overall prevalence of any vascular complications was 44.6%. Arterial thrombosis occurred in 20.4%, venous thromboembolism (VTE) in 11.3%, bleeding episodes in 24.7% of patients. Individuals harboring <italic>JAK2</italic> V617F mutation, regardless of MPN type, were at higher risk of VTE (OR = 5.15, 95%CI: 1.16-22.90, P = 0.024), mainly deep vein thrombosis (DVT). <italic>JAK2</italic> allele burden higher than 20% identified patients with 7.4-fold increased risk of VTE (95%CI: 1.6-33.7, P = 0.004), but not of arterial thrombosis, neither of bleeding complications, and remained the only significant VTE risk factor in multivariate logistic regression. High allele burdens (over 50%) were strikingly associated with proximal DVT cases, but not with distal DVT.</p> </sec> <sec> <title id="st0025">Conclusions</title> <p id="sp0020">The group of MPN patients with <italic>JAK2</italic> V617F allele burden higher than 20% may benefit the most from vigilant monitoring and appropriate prophylaxis against vascular events. Inclusion of <italic>JAK2</italic> V617F mutant allele burden in new risk stratifications seems to be justified and requires controlled prospective trials.</p> </sec> </abstract>